Who are NMBA - cisatracurium's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rocuronium + sugammadex, Rocuronium or Vecuronium, Neuromuscular Blocking Agents, Rocuronium dosing, Deep neuromuscular block, Vecuronium + Atracurium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nmba-cisatracurium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

NMBA - cisatracurium — Competitive Intelligence Brief

NMBA - cisatracurium (NMBA - cisatracurium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-depolarizing neuromuscular blocking agent (NMBA). Area: Anesthesiology.

marketed Non-depolarizing neuromuscular blocking agent (NMBA) Nicotinic acetylcholine receptor at the neuromuscular junction Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

NMBA - cisatracurium (NMBA - cisatracurium) — CHU de Reims. Cisatracurium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the neuromuscular junction to produce skeletal muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NMBA - cisatracurium TARGET	NMBA - cisatracurium	CHU de Reims	marketed	Non-depolarizing neuromuscular blocking agent (NMBA)	Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium + sugammadex	Rocuronium + sugammadex	Brno University Hospital	marketed	Neuromuscular blocking agent (rocuronium) + selective relaxant binding agent (sugammadex)	Nicotinic acetylcholine receptor at the neuromuscular junction (rocuronium); rocuronium molecule itself (sugammadex)
Rocuronium or Vecuronium	Rocuronium or Vecuronium	Merck Sharp & Dohme LLC	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction
Neuromuscular Blocking Agents	Neuromuscular Blocking Agents	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Neuromuscular blocking agent	Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium dosing	Rocuronium dosing	Clare Hayes-Bradley	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction
Deep neuromuscular block	Deep neuromuscular block	University of Medicine and Pharmacy at Ho Chi Minh City	marketed		Nicotinic acetylcholine receptor at the neuromuscular junction
Vecuronium + Atracurium	Vecuronium + Atracurium	Sir Ganga Ram Hospital	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-depolarizing neuromuscular blocking agent (NMBA) class)

CHU de Reims · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NMBA - cisatracurium — Competitive Intelligence Brief. https://druglandscape.com/ci/nmba-cisatracurium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab